[Translation] A Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetic characteristics of KX-826 gel 1.0% in Chinese adult subjects with acne vulgaris after multiple topical administration

评价KX-826凝胶1.0%在中国成年寻常痤疮受试者中局部外用多次给药的安全性、耐受性和药代动力学特征

[Translation]

To evaluate the safety, tolerability, and pharmacokinetic characteristics of KX-826 gel 1.0% after multiple topical administration in Chinese adult subjects with acne vulgaris

Start Date26 Apr 2024

Sponsor / Collaborator

Suzhou Pioneer Pharmaceutical Co., Ltd.

CTR20231724 / Active, not recruitingPhase 3

评价福瑞他恩（KX-826）酊外用治疗中国成年雄激素性秃发（AGA）患者的多中心、开放、安全性临床试验

[Translation] A multicenter, open, safety clinical trial to evaluate the topical use of Furetan (KX-826) tincture in the treatment of adult androgenetic alopecia (AGA) in China

主要目的：评价福瑞他恩(KX-826)酊外用治疗中国成年雄激素性秃发(AGA)患者的长期安全性次要目的：评价福瑞他恩(KX-826)酊外用治疗中国成年雄激素性秃发(AGA)患者的其他安全性指标评价福瑞他恩(KX-826)酊外用治疗中国成年雄激素性秃发(AGA)患者的有效性

[Translation]

Primary purpose: To evaluate the long-term safety of topical Furetan (KX-826) tincture in the treatment of Chinese adult patients with androgenetic alopecia (AGA) Secondary purpose: To evaluate other safety indicators of topical Furetan (KX-826) tincture in the treatment of Chinese adult patients with androgenetic alopecia (AGA) To evaluate the effectiveness of topical Furetan (KX-826) tincture in the treatment of Chinese adult patients with androgenetic alopecia (AGA)

Start Date12 Jul 2023

Sponsor / Collaborator

Suzhou Pioneer Pharmaceutical Co., Ltd.

NCT05218642 / CompletedPhase 2

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study in Male Subjects With Androgenetic Alopecia to Evaluate the Efficacy, Safety, and Tolerability of KX-826 Following Topical Multiple Dose Administration

The study is a randomized, double-blind, placebo-controlled, parallel group, phase 2 study to evaluate the efficacy, safety and tolerability of KX-826 in male subjects with androgenetic alopecia.

Start Date31 Jan 2022

Sponsor / Collaborator

Suzhou Kintor Pharmaceuticals, Inc.

100 Clinical Results associated with Pyrilutamide

100 Translational Medicine associated with Pyrilutamide

100 Patents (Medical) associated with Pyrilutamide

Literatures (Medical) associated with Pyrilutamide

01 Jan 2023·American journal of clinical dermatology

What’s New in Therapy for Male Androgenetic Alopecia?

Article

Author: Grimalt, Ramon ; Saceda-Corralo, David ; Domínguez-Santas, Miguel ; Vañó-Galván, Sergio

Male androgenetic alopecia is a common condition and represents a major concern for patients who experience this condition. While there are different treatments to stop hair loss and improve hair density, the 5-alpha reductase inhibitors have demonstrated to be effective in improving androgenetic alopecia in men and can maintain a positive response for many years. Oral finasteride 1 mg is a US FDA-approved option, but dutasteride 0.5 mg has been proven to induce better responses, especially in the frontal area. Both have been shown to be safe in clinical trials but there is widespread concern about sexual adverse effects among patients. The use of topical finasteride has increased during the last few years as a useful option to avoid systemic therapy. The efficacy of topical finasteride 0.25% daily has been demonstrated in clinical trials, with a less marked decrease in serum dihydrotestosterone levels than with oral intake. Mesotherapy with dutasteride has also become more widespread recently, although evidence of its effectiveness is limited to retrospective studies in real clinical practice. The use of oral minoxidil in androgenetic alopecia has not been approved by the FDA, however several clinical studies have shown that it is an effective treatment option. The initial dose recommended to treat male hair loss is 2.5 mg daily, although the dose is frequently increased to 5 mg daily. The main adverse effect of oral minoxidil is hypertrichosis, followed by dizziness or lower limb edema, which are much less common. Platelet-rich plasma is a non-pharmacological option to treat male androgenetic alopecia, with some clinical trials demonstrating an improvement in hair count after several months. Among the published studies, the main limitation to compare its efficacy is the heterogeneity of the procedure. The most frequent regimens propose treatment every 4 weeks for 3 months initially to assess the individual response. Another treatment alternative is the use of light devices with wavelengths of between 630 and 660 nm, known as low-level laser therapy. These devices can be used at home every day for 15-30 min. Their efficacy has been shown in a limited number of clinical trials; however, there is a lack of evidence about the efficacy of these devices compared with other medical options or as a complementary therapy in hair loss. The pipeline of potential new treatments for male androgenetic alopecia is strong. Pyrilutamide and GT20029 are being studied as topical antagonists of the androgen receptor, while cetirizine is another topical option with some initial promising results. Furthermore, according to isolated studies with heterogeneous treatment schemes, the use of botulinum toxin in the scalp might improve androgenetic alopecia, and lastly, scalp threading might increase the total hair count as growth factors are released during implantation.

01 Jan 2015·Evidence-based complementary and alternative medicine : eCAMQ4 · MEDICINE

Anti-Inflammatory and Cytostatic Activities of a Parthenolide-Like Sesquiterpene Lactone fromCota palaestinasubsp.syriaca

Q4 · MEDICINE

ArticleOA

Author: Al Aaraj, Lamis ; Talhouk, Salma N. ; Ghaddar, Tarek H. ; Saliba, Najat A. ; Nahhas, Rana ; Nasr, Bilal ; Fares, Mohamed-Bilal ; Ajeeb, Bushra ; Talhouk, Rabih S.

A sesquiterpene lactone 1-β,10-Epoxy-6-hydroxy-1,10H-inunolide (K100) was isolated through “bioassay-guided fractionation” fromCota palaestinasubsp.syriaca, an Eastern Mediterranean endemic plant. K100 inhibited endotoxin- (ET-) induced proinflammatory markers: IL-6, MMP-9, and NO in normal mouse mammary SCp2 Cells. Molecular dockingin silicosuggested that K100, having highly analogous structure as parthenolide (PTL), an anticancer compound, could bind PTL target proteins at similar positions and with comparable binding affinities. Both compounds, K100 and PTL, inhibited the proliferation and prolonged the S-phase of the cell cycle of breast adenocarcinoma MDA-MB-231 cells grown in 2D cultures. Noncytotoxic concentrations of K100 and PTL decreased the proliferation rate of MDA-MB-231 and shifted their morphology from stellate to spherical colonies in 3D cultures. This was accompanied with a significant increase in the amount of small colonies and a decrease in the amount of large colonies. Moreover, K100 and PTL decreased cellular motility and invasiveness of MDA-MB-231 cells. In summary, these results suggest that K100 exhibits PTL-analogous anti-inflammatory, cytostatic, and antimetastatic effects.

01 May 2014·Drug development and industrial pharmacyQ4 · MEDICINE

Loratidine buccal films for allergic rhinitis: development and evaluation

Q4 · MEDICINE

Article

Author: Bandar E Al-Dhubiab ; Anroop B Nair ; Rachna Kumria

The objective of this study was to develop a novel patient compliant buccoadhesive film capable of providing a prolonged protection against allergic symptoms. Polymeric buccoadhesive films of loratidine were prepared using hydroxypropylmethyl cellulose (HPMC)-E5 and K100 blend and Eudragit® NE 30D as retardant. Films were prepared using solvent-casting method. The developed films were evaluated for physical properties, hydration, mucoadhesion time, drug release, etc. All the prepared films exhibited excellent mechanical strength and uniform drug content. Increase in drug content did not influence the physicomechanical properties of the film. The mucoadhesive strength of films was significantly enhanced with increase in HPMC content. Increase in Eudragit® NE 30 D content in the film decreases the hydration, erosion and drug release, but enhances the mucoadhesion time. Furthermore, the release of loratidine from the prepared films followed Hixson-Crowell kinetics. Studies in healthy human volunteers using placebo films indicate that the prepared films possess prolonged mucoadhesion in-vivo, and this could potentially lead to clinically relevant drug delivery system.

News (Medical) associated with Pyrilutamide

19 Jul 2023

·www.prnewswire.com

Kintor Pharma Announces Completion of First Patient Enrollment in Long-term Safety Phase III Trial of KX-826 for Treatment of AGA

SUZHOU, China, July 19, 2023 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the company has initiated the long-term safety trial (the "Long-term Safety Trial") of KX-826, a potential first-in-class androgen receptor (AR) antagonist for the treatment of androgenetic alopecia (AGA) developed in-house, in China and has completed the first patient enrollment today. The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023. The Long-term Safety Trial is a multi-center, open-label Phase III clinical trial, which involves a total of 16 clinical research centers in China, with Professor Jianzhong Zhang of Peking University People's Hospital as the leading principal investigator (leading PI). A total of 270 male and female AGA patients will be enrolled to evaluate the long-term safety of the topical use of KX-826 for the treatment of AGA patients in China (treatment period of 52 weeks). The primary endpoint of the trial is the incidence of treatment emergent adverse events (TEAE). Secondary endpoints include efficacy as measured by the change in target area non-vellus hair count (TAHC) from baseline and other safety indicators. Previously, Kintor Pharma has successfully completed the Phase II clinical trial for male in China, the Phase II clinical trial for female in China and the Phase II clinical trial for male in the United States for KX-826 in the treatment of AGA. In each trial, after 24-week administration, KX-826 improved hair growth and showed a good safety profile. Most of the adverse events occurred during the study were mild, and similar to placebo, no TEAE resulting in patient withdrawal from the trial, nor death was reported. The Long-term Safety Trial will further explore the long-term safety and efficacy of KX-826 in the treatment of AGA on the basis of the safety profile and efficacy of above mentioned trials, which will help provide more data to support the use of such medication for long-term treatment for AGA patients. About Kintor Pharmaceutical Limited Kintor Pharmaceutical Limited is developing and commercializing a robust pipeline of innovative small molecule and biological therapeutics for oncology and androgen-receptor-related disease areas with unmet medical needs, including alopecia, acne, COVID-19, prostate cancer, liver and breast cancers. For more information, visit . SOURCE Kintor Pharma

Phase 2Phase 3

11 May 2023

·www.prnewswire.com

Kintor Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US

SUZHOU, China, May 11, 2023 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the Phase II clinical trial of in-house developed KX-826 for the treatment of male androgenetic alopecia ("AGA") in the US has been completed successfully. The results are statistically and clinically meaningful, and demonstrated a favorable safety profile. The company is preparing for subsequent FDA meetings on the results of the Phase II clinical trial, and intends to commence Phase III clinical trial in the US/globally. Results of the Phase II clinical trial showed that KX-826 promotes hair growth compared to baseline and demonstrated statistical and clinically meaningful as measured by target area non-vellus hair count ("TAHC"). KX-826 has indicated an improvement in TAHC versus placebo, and a dose-response relationship was observed from different KX-826 dosage groups. The Phase II clinical trial is a randomized, double-blind, placebo-controlled and parallel group study designed to evaluate the efficacy and safety of KX-826 for the treatment of male AGA. A total of 123 male AGA patients, who were classified into stage III vertex, IV or V using the Hamilton-Norwood scale, were enrolled in the Phase II clinical trial. Among them, 93 patients were randomly assigned to different dosage groups, including 0.25% once daily ("QD"), 0.5% QD and 0.5% twice daily ("BID"); and 30 patients were randomly assigned to placebo groups receiving different dosages. The results showed that: The TAHC of the 0.5% BID KX-826 group has increased by about 10 hair counts per cm2 compared with baseline after the treatment of 24 weeks, which was statistically significant (P=0.0088). KX-826 has indicated an improvement in TAHC versus placebo, and a dose-response relationship was observed from different KX-826 dosage groups. Other relevant results indicated that KX-826 promotes hair growth clinically in male AGA patients. Same with the Phase II clinical trial in China, 0.5% BID KX-826 was determined to be the optimal dose in the Phase II clinical trial. 0.5% BID KX-826 was also determined to be the recommended dose for Phase III clinical trial for male AGA in the US/globally. KX-826 demonstrated a favorable safety profile in male AGA treatment. In our study, most of the treatment emerged adverse events ("TEAE") were mild and local scalp sensitivity similar to those of placebo in terms of occurrences. No TEAE resulting in patient withdrawal from the trial, nor death was reported. Multiple clinical trials on KX-826 in China and the US for male and female AGA treatments are currently ongoing. On 1 December 2022, the company announced that the primary endpoint of Phase II clinical trial of KX-826 in China for the treatment of female AGA patients was met. On 28 March 2023, the company announced that the enrollment of patients for the Phase III clinical trial KX-826 in China for the treatment of male AGA was completed, and the top-line data of which was expected to be released in the fourth quarter of 2023. About Kintor Pharmaceutical Limited Kintor Pharmaceutical Limited is developing and commercializing a robust pipeline of innovative small molecule and biological therapeutics for oncology and androgen-receptor-related disease areas with unmet medical needs, including alopecia, acne, COVID-19, prostate cancer, liver and breast cancers. For more information, visit . SOURCE Kintor Pharma

Phase 2Clinical Result

30 Mar 2023

·www.biospace.com

Kintor Pharma Announces 2022 Annual Results and Recent Business Progress

SUZHOU, China, March 30, 2023 /PRNewswire/ -- Kintor Pharmaceutical Limited (Kintor Pharma, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced business highlights and financial results for the year ended 31 December 2022. Business Highlights Kintor Pharma has made rapid progress on global clinical development, and achieved positive data read-outs of core products during the reporting period. Kintor Pharma has rolled out the clinical pipeline in dermatology area globally. Kintor Pharma is actively promoting the business development opportunities in China and globally to accelerate the commercialization progress. Kintor Pharma has raised about $100 million through 2 top-up placements during the reporting period. The company's stock has been included in MSCI China Index and Shanghai-Hong Kong Stock Connect, which increased the stock's liquidity in the capital market. The company's R&D outcome has been accepted by reputable academic conferences including AACR, ASH and AAD of the U.S., which has demonstrated its R&D capabilities. Dr. Youzhi Tong, founder, Chairman, and CEO of Kintor Pharma, commented, 2022 has been a challenging year for the global biotech industry. Under the difficulty market conditions, Kintor Pharma has made rapid progress in R&D, financing and academic publications. In terms of R&D, the company has made steady progress in its pipeline and achieved positive data read-outs of its core products, including Pyrilutamide (KX-826) for androgenetic alopecia (AGA) indication, GT20029 for AGA and acne vulgaris indications. The Phase II clinical trials of KX-826 for male and female AGA in China have reached the primary endpoints, respectively. Kintor Pharma has rolled out the clinical pipeline in dermatology area globally, and is actively promoting the business development opportunities in China and globally to accelerate the commercialization progress. In capital market, the company has raised net proceeds of $100 million through two top-up placements during the reporting period. In addition, the company's stock has been included in the MSCI China Index and the Shanghai-Hong Kong Stock Connect, further enhanced the stock's liquidity in the capital market. In academics, the company's research results have been presented at important academic conferences such as AACR, ASH and AAD of the U.S., proving that the company's innovation ability and its international influence. Looking forward, Kintor Pharma will continue to execute the development of the core products in China and globally, expecting to accelerate its commercialization process. The company strives to bring safe and effective therapeutics to the patients around the globe, and create value for its shareholders and employees. Rapid Progress on Global Clinical Development and Positive Data Read-outs of Core Products As a Biotech company focusing on the R&D and industrialization of potential First-in-Class and Best-in-Class innovative drugs, Kintor Pharma has developed a diversified product pipeline including small-molecule drugs, biologics innovative drugs and combination therapies. At present, the company has seven novel drug candidates with First-in-Class or Best-in-Class potential in Phase I-III clinical stages in China and around the world. Since 2022, the company has released positive clinical results of core products, including the Phase II clinical trials of KX-826 for male and female AGA in China, respectively, and the Phase I clinical trials of GT20029 for the treatment of AGA and ance in both China and the U.S.. Pyrilutamide (KX-826) is a topical androgen receptor (AR) antagonist that is under clinical development for the potential treatment of AGA and acne. KX-826 is the world's first AR antagonist for AGA treatment which entered the Phase III clinical trial stage. On 27 August 2022, one of the leading principal investigators of the Phase II clinical trial of KX-826 in China for the treatment of male AGA adults, Professor Jianzhong Zhang (张建中) from Peking University People's Hospital, released the trial's positive results at the 6th Annual Meeting of Chinese Hair Research Society (第六届全国毛发学术会议). The results showed that after 24 weeks of treatment, the non-vellus target area hair counts (TAHC) in the 5mg (0.5% concentration) twice daily (BID) KX-826 group increased by 15.34/cm2 compared with the placebo group from baseline, with a statistical difference (P=0.024). On 1 December 2022, the company announced that the primary endpoint of Phase II clinical trial of KX-826 for female AGA adults in China was met. After 24 weeks of treatment, the non-vellus TAHC in the 5mg (0.5% concentration) once daily (QD) KX-826 group increased by 11.39/cm2 compared with the placebo group from baseline, with a statistical difference (P=0.0087). KX-826 has showed a good safety pro both trials. GT20029 is a topical AR-Proteolysis Targeting Chimera (PROTAC) compound that is under clinical development for the potential treatment of AGA and acne. GT20029 is the world's first topical PROTAC compound which entered the clinical stage. On 24 November 2022, the company announced the top-line data of the Phase I clinical trial of GT20029 for the treatment of AGA and acne in China. The results showed that GT20029 demonstrated good safety, tolerability and pharmacokinetics in healthy subjects. On 10 February 2023, the company announced the top-line data of the Phase I clinical trial of GT20029 for the treatment of AGA and acne in the U.S.. The results showed that GT20029 demonstrated good safety, tolerability and pharmacokinetics following topical single ascending dose (SAD) administration in healthy subjects and multiple ascending dose (MAD) administration in subjects with AGA or acne. In addition, the company's product pipeline includes Pruxelutamide, GT1708F, GT0486, ALK-1 antibody (GT90001) and GT90008 in the clinical stage, and c-Myc inhibitor, compound of other targets out of PROTAC platform and ALK-1/VEGF bispecific antibody in the preclinical stage. The company's Hedgehog/SMO inhibitor GT1708F is being explored for both idiopathic pulmonary fibrosis (IPF) indication and combination therapy in blood cancer. The company is now preparing for clinical trial application for the IPF indication. The Growing Visibility in the Capital Market Since its listing on the Hong Kong Stock Exchange on 22 May 2020, the company's development has received long-term support from investors around the world. In 2022, the company successfully completed two top-up placements in the capital market and raised about $100 million. After being included in the Hong Kong Stock Connect program in September 2021, the company's stock has been included in the Shanghai-Hong Kong Stock Connect in March 2023, further expanding the company's mainland investor pool, improving its liquidity and the market influence. Thus benefits the company's future development prospects. In addition, Kintor Pharma's stock have been included in the MSCI China Index during the reporting period. Increasing Presence in Reputable Academic Seminars and Conferences Since 2022, Kintor Pharma's R&D outcome has been accepted by reputable academic conferences and journals, proving that the company's innovation ability and its international influence, and further demonstrating the First-in-Class and Best-in-Class potential of the company's product pipeline. Kintor Pharma's KX-826 and GT20029 for treatment of AGA and acne presented at AAD 2023 Kintor Pharma's Hedgehog/SMO inhibitor GT1708F for the treatment of Acute Myeloid Leukemia (AML) presented at AACR 2023 Oral Presentation highlighting the data from novel dual c-Myc/GSPT1 degrader GT19715 at ASH 2022 Pruxelutamide for treatment of COVID-19 and a c-Myc degrader for treatment of blood cancer and small cell lung cancers (SCLC) presented at AACR 2022 The study result of GT19715, a novel dual-target degrader of C-Myc/GSPT1, was published in the journal Clinical Lymphoma, Myeloma & Leukemia The study result of the Phase Ib clinical trial of Pruxelutamide for treatment of breast Cancer was published in the European Journal of Cancer (EJC) Industry and Capital Market Awards Kintor Pharma's persistent efforts in R&D has been widely recognized in the industry and has won many industry and capital market awards. Top 15 Biotech of the Top 100 Hong Kong Listed Companies Top 10 Innovative Pharmaceutical Companies in 2022 R&D Innovation Outstanding Contribution Award in 2021 Top 20 Biomedical Innovation Potential List in 2022 TOP 30 Innovative Small Molecule Pharmaceutical Companies in China in 2021 TOP 20 Most Influential Small Molecule Pharmaceutical Innovation Companies in 2022 Jishi Cup Top 10 Pharmaceutical Innovation Companies in 2021 Most Valuable Pharmaceutical and Medical Companies Other Business Updates In August 2022, Dr. Lu Qun, our Chief Technology Officer, was elected as a "2022 Gusu Innovation and Entrepreneurship Leading Talent". In May 2022, the company has received the approval to set up a Doctors workstation in Guangdong Province by the Human Resources and Social Security Department of Guangdong Province. Financial Highlights As of 31 December 2022, the company's research and development costs increased by RMB828 million, up by 7.8%, from RMB767.9 million for the year ended 31 December 2021. The increased R&D costs were mainly attributable to the ongoing Phase III clinical trials, including those of Pruxelutamide for the indication of COVID-19 and mCRPC, and KX-826 for the indication of AGA during the reporting period. The company had cash and cash equivalents and time deposits of RMB875.3 million as at 31 December 2022, including utilised bank facilities of RMB 276.5 million. In addition, the company also had unutilised bank facilities of RMB 120.0 million as at 31 December 2022. The company has sufficient cash on hand to support the advancement of the clinical trials and R&D. *For more details, please refer to the 2022 annual results announcement. About Kintor Pharmaceutical Limited Kintor Pharmaceutical Limited is developing and commercializing a robust pipeline of innovative small molecule and biological therapeutics for androgen-receptor-related disease areas with unmet medical needs, including COVID-19, prostate, breast and liver cancers, alopecia and acne. For more information, visit . Company Codes: HongKong:9939

Phase 1Clinical ResultPhase 2Financial Statement

100 Deals associated with Pyrilutamide

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Androgenetic Alopecia	Phase 3	CN	Suzhou Pioneer Pharmaceutical Co., Ltd.	29 Dec 2021
Androgenetic Alopecia	Phase 3	CN	Suzhou Kintor Pharmaceuticals, Inc.	29 Dec 2021
Acne Vulgaris	Phase 2	CN	Suzhou Pioneer Pharmaceutical Co., Ltd.	04 Jun 2024
Alopecia, Male Pattern	Phase 2	US	Suzhou Kintor Pharmaceuticals, Inc.	31 Jan 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


CTR20213036 (NEWS) Manual	Phase 3	Androgenetic Alopecia	740	KX-826	ivmpaqwwsf(oxcayjuivf) = KX-826组TAHC结果显示，KX-826与基线相比促进了毛发生长，具有统计学意义(P<0.0001)。与安慰剂相比，KX-826组TAHC在各个访视点均有提高，差异在统计学上未达到显着性，但显示疗效趋势。 lfluyecpaf (fjvtpgpxgu ) Not Met View more	Negative	27 Nov 2023
				placebo
EADV2023	Phase 2	Androgenetic Alopecia	120	KX-826 0.5% BID	cvolrjswei(qhemxpsoub) = ptbtcfsqwg robkudprbs (pllasqfuvv )	Positive	11 Oct 2023
				Placebo BID	cvolrjswei(qhemxpsoub) = uhzwqjyisj robkudprbs (pllasqfuvv )
KX826-CN-1004 (EADV2023)	Phase 2	Alopecia	160	0.5% QD KX-826	umpmpdanbx(uqixqmbhzp) = cbrtrsazia hjsyyeafgp (rtdshtyzpn )	Positive	11 Oct 2023
				Placebo	umpmpdanbx(uqixqmbhzp) = arkcugtoao hjsyyeafgp (rtdshtyzpn )
KX826-CN-1004 (EADV2023)	Phase 2	Alopecia	160	0.5% QD KX-826	vaafcxyidx(bqjfhivsvo) = sngrtbpccr jkcbefjscw (fnttbkoijq )	Positive	11 Oct 2023
				Placebo	vaafcxyidx(bqjfhivsvo) = phipwbtflm jkcbefjscw (fnttbkoijq )
NCT05218642 (Biospace) Manual	Phase 2	Androgenetic Alopecia	123	KX-826 0.5% BID	fdsojgqebq(wwocyxdshz) = rdjoxedovf jvgafyfchj (xokxygwddn )	Positive	11 May 2023
				placebo	-
CTR20212684 (PRNewswire) Manual	Phase 2	Androgenetic Alopecia	160	KX-826	yujcicjoxh(hrwvdweryg): difference = 11.39, P-Value = 0.0087 View more	Positive	01 Dec 2022
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Pyrilutamide

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation